Results 21 to 30 of about 25,343 (258)

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease [PDF]

open access: yes, 2003
Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-
Krack, P.   +11 more
core   +4 more sources

L-dopa: main drug induced dyskinesia

open access: yesSão Paulo Medical Journal, 2021
Introduction: 3,4-dihydroxy-L-phenylalanine (L-dopa) is the gold standard drug for the treatment of Parkinson’s disease (PD). This disease causes degeneration of dopaminergic cells, L-dopa supplies the lack of dopamine, being effective in its treatment.
Pedro Felisberto Nogueira Viana Farah   +4 more
openaire   +1 more source

Tardive dyskinesia on clozapine: A case report

open access: yesSouth African Journal of Psychiatry, 2009
Antipsychotic-induced tardive dyskinesia is a potentially irremediable and debilitating condition with the onset most commonly associated with the use of first-generation antipsychotics.
Laila Asmal
doaj   +1 more source

Dystonia and paroxysmal dyskinesias: under-recognized movement disorders in domestic animals? A comparison with human dystonia/paroxysmal dyskinesias. [PDF]

open access: yes, 2015
Dystonia is defined as a neurological syndrome characterized by involuntary sustained or intermittent muscle contractions causing twisting, often repetitive movements, and postures.
Albanese   +116 more
core   +2 more sources

Relevance of animal models to human tardive dyskinesia

open access: yesBehavioral and Brain Functions, 2012
Tardive dyskinesia remains an elusive and significant clinical entity that can possibly be understood via experimentation with animal models. We conducted a literature review on tardive dyskinesia modeling.
Blanchet Pierre J   +3 more
doaj   +1 more source

Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia

open access: yesБюллетень сибирской медицины, 2020
Purpose. To analyze the results of classical and modern studies reflecting the pathophysiological mechanisms of antipsychotic-induced tardive dyskinesia.Materials and methods. We searched for full-text publications in Russian and English in the databases
E. E. Vayman   +3 more
doaj   +1 more source

The differential diagnosis of chorea [PDF]

open access: yes, 2007
Chorea is a hyperkinetic movement disorder characterised by excessive spontaneous movements that are irregularly timed, randomly distributed and abrupt. In this article, the authors discuss the causes of chorea, particularly Huntington's disease and the ...
Tabrizi, SJ, Wild, EJ
core   +1 more source

Antipsychotic Drug Induced Tardive Dyskinesia

open access: yesInternational Journal of Research in Pharmaceutical Sciences, 2020
A typical antipsychotics are at a lower risk of developing extra-pyramidal symptoms (EPS). But now, atypical antipsychotics are increasingly being associated with neurological side effects such as tardive dyskinesia, tardive dystonia, akinesia, parkinsonism, akathisia, bradykinesia, tremor etc.
null Gopika S Kumar   +3 more
openaire   +1 more source

Failure of pyridoxine to reduce drug-induced dyskinesias [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 1970
The use of pyridoxine seems to be ineffective in reducing tardive dyskinesia.
G E, Crane, I S, Turek, A A, Kurland
openaire   +2 more sources

Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. [PDF]

open access: yes, 2012
Paroxysmal nonkinesigenic dyskinesia (PNKD) is an autosomal dominant episodic movement disorder. Patients have episodes that last 1 to 4 hours and are precipitated by alcohol, coffee, and stress.
Edwards, Robert H   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy